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Objectives: This study aimed to elucidate the relative involvement of drug resistance gene
copy number and overexpression in fluconazole resistance in clinical C. glabrata isolates
using a population-based approach.
Methods: Fluconazole resistance levels were quantified using the minimal inhibitory
concentration (MIC) via Etest method. Both gene expression levels and gene copy number
of CgCDR1, CgPDH1, CgERG11, and CgSNQ2 were assessed via quantitative real-time
PCR. The influence of the main effects and first-level interactions of both the expression
level and copy number of these genes on fluconazole resistance levels were analyzed
using a multivariate statistical model.
Results: Forty-three C. glabrata isolates were collected from 30 patients during in
a hospital survey. In the multivariate analysis, C. glabrata fluconazole MICs were
independently increased by CgSNQ2 overexpression (p < 10−4) and the interaction
between CgPDH1 gene copy number and CgPDH1 expression level (p = 0.038). In
contrast, both CgPDH1 overexpression (p = 0.049) and the interaction between CgSNQ2
and CgERG11 expression (p = 0.003) led to a significant decrease in fluconazole MICs.
Conclusion: Fluconazole resistance in C. glabrata involves complex interactions between
drug resistance gene expression and/or copy number. The population-based multivariate
analysis highlighted the involvement of the CgSNQ2 gene in fluconazole resistance and
the complex effect of the other genes such as PDH1 for which overexpression was
associated with reduced fluconazole resistance levels, while the interaction between
PDH1 overexpression and copy number was associated with increased resistance levels.
Keywords: Candida glabrata, fluconazole, resistance mechanisms, gene expression, gene copy number,
quantitative real-time PCR, human infection
INTRODUCTION
Candida glabrata is responsible for the increase in cases of sys-
temic and superficial candidiasis in many countries (Diekema
et al., 2002; Li et al., 2007; Pfaller and Diekema, 2007). Several
reports have revealed that a significant percentage of C. glabrata
clinical isolates are resistant to fluconazole. Pfaller et al. have
found that between 2001 and 2007, isolation frequencies and
fluconazole resistance among C. glabrata blood stream infec-
tion isolates was increased compared with the 1992–2001 period
(Pfaller and Diekema, 2004; Pfaller et al., 2009). Similarly, anti-
fungal susceptibility surveys have detected 17 and 18% resistance
levels in Europe and North America, respectively (Pfaller et al.,
2009). Many studies have shown that drug efflux mediated by
the overexpression of ATP-binding cassette (ABC) transporter
family membrane proteins was the main molecular mechanism
associated with C. glabrata fluconazole resistance (Sanglard et al.,
1999, 2001; Bouchara et al., 2000; Niimi et al., 2002; Wada et al.,
2002; Cernicka and Subik, 2006; Coleman and Mylonakis, 2009).
Studies have also shown that among ABC transporters, CgCDR1,
and CgPDH1, but not CgSNQ2, play a major role in flucona-
zole resistance (Sanguinetti et al., 2005; Torelli et al., 2008). Azole
resistance in C. albicans was primarily associated with mutation
or overexpression of ERG11, which encodes the key azole tar-
get protein lanosterol 14-alpha demethylase (Chau et al., 2004;
Cernicka and Subik, 2006). In contrast, CgERG11 mutations
were marginally involved in C. glabrata fluconazole resistance
(Sanguinetti et al., 2005). However, CgERG11 overexpression has
been associated with chromosome duplication and aneuploidy
due to genome plasticity as well as fluconazole resistance in
Cryptococcus neoformans, C. albicans, and C. glabrata (Marichal
et al., 1997; Kwon-Chung and Chang, 2012). This study aimed
to dissect the relative contribution of drug resistance gene copy
number and overexpression on fluconazole resistance in clinical
C. glabrata isolates.
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METHODS
PATIENTS AND ISOLATES
The population of Candida glabrata clinical isolates included in
the present study were recovered during an epidemiological sur-
vey of antifungal resistance conducted at the Habib Bourguiba
University Hospital in Sfax from January 2005 to December 2007
as previously described (Abbes et al., 2011, 2012; Amouri et al.,
2011; Sellami et al., 2011). The specimens were isolated from
30 patients with urinary tract infection, vaginal infection or sys-
temic infections. Candida glabrata was identified by assessing
the isolates using Candiselect medium (bioMérieux, Craponne,
France) and the ID32C profile (bioMérieux). Isolate fluconazole
minimum inhibitory concentrations (MICs) were then measured
using the E-test method (AB Biodisk, Sweden) on RPMI 1640
medium (AES, France) as recommended by the manufacturer.
Isolates with MICs>64mg/l were defined as fluconazole resistant
(Clinical and Laboratory Standards Institute, 2008).
RNA AND DNA ISOLATION
Total RNA was extracted from yeast cells isolated from RPMI
plates during the logarithmic growth phase at 48 h of incuba-
tion using an RNAeasy Protect™ mini kit (Qiagen, Courtaboeuf,
France) according to the manufacturer’s instructions. RNA
extracts were treated with RNase-free DNase (Qiagen) to
avoid DNA contamination. Genomic DNA was extracted using
the NucleoSpin™ Tissue method (Macherey-Nagel, Dueren,
Germany) according to themanufacturer’s instructions. Genomic
DNA (gDNA) extracts were treated with DNase-free RNase
(Qiagen) to eliminate RNA contamination.
QUANTITATIVE REAL-TIME PCR
Quantitative real-time PCR analysis was performed to measure
the expression levels and copy number of each of the four tar-
get genes: CgCDR1, CgPDH1, CgSNQ2, and CgERG11 (Table 1).
Gene transcript levels and copy number values were normalized
to URA3, a single copy gene encoding orotidine 5-phosphate
decarboxylase.
Reverse transcriptase PCR (RT-PCR)
First, the RNA extract of each isolate was transcribed into cDNA
using reverse transcriptase (RT), which was performed with a
25-µl reaction volume containing 2.5µl MuLva buffer (Biology,
France), 2U of MuLva RT (Biology), 5µl RNA sample and
0.5µM random primer and polyA mixture (Eurogentec, France).
The samples were subjected to reverse transcription at 37◦C for
60min.
Quantitative real-time PCR (qPCR)
Two µl of either cDNA or gDNA template was used to sep-
arately assess expression levels and gene copy number of the
four genes: CgCDR1, CgPDH1, CgSNQ2, and CgERG11, as pre-
viously described (Sanguinetti et al., 2005). The primers utilized
are detailed in Table 1. Briefly, 200 pM of each primer, 200 pM
hydrolysis probe and 25µl TaqMan mix (Applied Biosystems,
Courtaboeuf, France) were included in the PCR assay. Copy num-
ber PCR cycling conditions consisted of an initial step at 94◦C for
10min and then 40 cycles of 15 s at 94◦C, 30 s at 55◦C and 20 s at
Table 1 | Primers and probes used to amplify CgCDR1, CgPDH1
(formerly denoted CDR2), CgSNQ2, CgERG11, and CgURA3 in
separate quantitative Real-Time PCR reactions as described in Wada
et al. (2002).
Gene Primer Sequence Annealing
(genbank or probe site (5′–3′)
accession no)
CgCDR1
(AF109723)
CDR1a TAGCACATCAACTACACGAACGT 4500–4522
CDR1b AGAGTGAACATTAAGGATGCCATG 4647–4670
CDR1pr 6FAM-TGCTGCTGCTTCTGCCACC
TGGTT-TAMRA
4621–4644
CgPDH1
(AF251023)
CDR2a GTGCTTTATGAAGGCTACCAGATT 164–187
CDR2b TCTTAGGACAGAAGTAACCCATCT 251–274
CDR2pr 6FAM-TACCTTTGCGTGCTGGGC
GTCACC-TAMRA
217–240
CgSNQ2
(AF251022)
SNQ2a ACCATGTGTTCTGAATCAATCAAT 360–383
SNQ2b TCGACATCATTACAATACCAGAAA 462–485
SNQ2pr 6FAM-AACTAATCGCCGCAGGTTG
TGACA-TAMRA
394–317
CgERG11
(L40389)
ERGa ATTGGTGTCTTGATGGGTGGTC 928–949
ERGb TCTTCTTGGACATCTGGTCTTTCA 1019–1042
ERGpr 6FAM-ACTTCCGCTGCTACCTCCG
CTTGG-TAMRA
955–978
CgURA3
(L13661)
URAa GAAAACCAATCTTTGTGCTTCTCT 168–191
URAb CATGAGTCTTAAGCAAGCAAATGT 268–291
URApr VIC-ACGTCACCACCACCAGCG
AATTGT-TAMRA
194–217
72◦C. Fluorescence data were collected during the extension step
and analyzed with a MX 4000 real-time PCR system (Stratagene,
France). Each reaction was performed in duplicate. Copy number
efficiency was determined for each gene. The normalized relative
quantities of the gene-specific product or copy number for each
sample were then calculated, i.e., the quantity of the samples of
interest was compared with a calibrator (TU10, a fluconazole sus-
ceptible control, MIC = 0.125mg/l). The quantity of both the
calibrator and the samples of interest were normalized to URA3.
C. glabrata GENOTYPING
The C. glabrata isolates were genotyped using six markers, five
microsatellites (RPM2, MTI, GLM4, GLM4, and GLM6) and
irregular patterns in the ERG3 gene as previously described
(Abbes et al., 2011, 2012).
STATISTICAL ANALYSIS
Normalized gene copy numbers and expression levels are indi-
cated using range, median, and interquartile range (IQR). The
correlation between fluconazole MICs and the relative expres-
sion level and copy number of each gene was analyzed using the
Spearman rank correlation coefficient. For qualitative analysis, we
selected a threshold value of 2.5 normalized gene expression or
normalized gene copy number to define gene overexpression or
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Table 2 | Relative gene expression levels and copy numbers of CgCDR1, CgPDH1, CgERG11, and CgSNQ2 in fluconazole sensitive and resistant
Candida glabrata isolates.
Patients Isolates Sample Microsatellite Fluconazole Relative increase in
site type MIC (µg/ml)
CDR1 CDR1 PDH1 PDH1 ERG11 ERG11 SNQ2 SNQ2
expression copies expression copies expression copies expression copies
1 1.1 Urine 3 1.5 3.09 4.59 6.62 1.99 0.4 0.74 1.11 0.18
1 1.2 Urine 3 256 5.64 4.7 20.04 4.13 0.54 1549.94 0.48 364.12
2 2.1 Urine 5 16 ND 2.01 ND 1.85 ND 1.55 ND 2.13
2 2.2 Urine 5 256 92.61 1.83 169.56 1.37 0.12 1.6 5.41 0.94
3 3.1 Vaginal 9 2 0.12 2.16 0.44 1.61 0.24 2.3 0.07 1.58
3 3.2 Vaginal 9 256 0.29 2.18 0.57 1.27 1.16 1.41 0.19 1.65
4 4.1 Urine 1 4 ND 1.48 0.11 1.14 0.53 3.35 0.04 0.99
4 4.2 Urine 1 256 0.1 2.32 9.42 0.83 0.3 3.14 1.19 1.44
5 5 Urine 1 256 1.84 1.11 7.64 1.16 0.56 0.91 0.97 1.22
6 6.1 Urine 8 32 0.1 1.02 0.49 0.9 0.94 0.93 0.56 0.82
6 6.2 Urine 2 256 2.54 4.04 375.57 5.7 4.34 12.7 73.61 0.56
7 7 Blood
culture
7 256 0.39 1.89 5.6 2.71 0.42 2.01 5.77 1.2
8 8 Urine 9 256 12.06 3.64 0.31 3.21 0.23 3.74 1.17 3.24
9 9 Blood
culture
7 256 12.14 1.27 0.59 0.89 0.87 1.01 2.17 1.03
10 10 Blood
culture
7 32 1.42 1.25 0.27 1.01 0.25 1.84 0.26 1.56
11 11.1 Urine 12 1 0.34 ND 15.08 ND 1.11 ND 12.93 ND
11 11.2 Urine 4 32 0.46 1.21 4.86 1.38 0.57 0.79 0.45 1.04
11 11.3 Urine 10 32 0.65 1.25 0.87 0.86 0.54 1.84 1.72 ND
12 12 Blood
culture
10 1 0.43 1.41 0.46 2.05 0.09 1.45 0.01 1.28
13 13 Blood
culture
6 2 ND 1.73 0.04 1.21 0.27 1.29 0.22 0.85
14 14 Blood
culture
10 2 0.3 1.68 0.26 1.17 0.16 1.68 0.37 1.39
15 15 Kidney
abscess
13 3 ND 1.59 0.76 1.93 0.42 1.6 0.99 0.7
16 16 Lung
abscess
14 2 0.23 1.24 0.35 0.79 0.31 1.07 0.47 0.95
17 17 Urine 14 2 0.18 1.75 0.46 1.52 0.26 3.86 0.42 0.77
18 18 Blood
culture
15 2 0.09 1.74 0.25 0 0.26 2.1 0.3 1.12
19 19.1 Urine 7 0.064 0.019 1.26 0.94 1.32 1.23 1.19 0.49 1.31
19 19.2 Urine 7 0.125 0.04 1.2 0.79 1.14 0.38 0.99 0.52 0.69
20 20 Blood
culture
7 4 1.3 1.47 17.05 1.67 1.78 1.32 0.48 1.83
21 21.1 Urine 4 6 6.71 1.16 3.59 1.25 2.34 4.03 3.56 0.41
21 21.2 Urine 4 4 0.86 2.76 0.74 2.57 0.71 2.57 0.69 2.82
21 21.3 Urine 4 4 0.82 1.4 0.96 1.51 1.32 1.38 0.79 1.67
21 21.4 Urine 4 8 0.01 2.16 0.57 1.61 1.89 2.3 1.72 1.75
21 21.5 Urine 4 4 2.63 2.31 2.9 1.96 1.05 1.76 2.14 1.6
22 22 Blood
culture
3 4 1.59 1.71 1.13 1.75 0.74 1.34 1.18 1.43
23 23 Urine 4 4 1.81 1.62 2.79 1.48 0.52 1.46 1.79 1.61
24 24 Urine 16 4 0.12 1.71 0.29 1.18 0.43 1.1 0.25 1.28
25 25 Urine 10 0.5 0.03 ND 1.61 2.61 0.09 1.36 0.1 48.88
26 26.1 Urine 9 0.016 ND 4.19 2.76 2.23 1 1.15 0.35 0.37
26 26.2 Urine 9 6 0.4 ND 0.88 ND 0.84 ND 0.59 ND
(Continued)
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Table 2 | Continued
Patients Isolates Sample Microsatellite Fluconazole Relative increase in
site type MIC (µg/ml)
CDR1 CDR1 PDH1 PDH1 ERG11 ERG11 SNQ2 SNQ2
expression copies expression copies expression copies expression copies
27 27 Blood
culture
11 8 ND ND 0.76 ND 0.7 ND 0.15 ND
28 28 Blood
culture
3 1 0.2 4.27 1.16 2.41 2.09 1.59 0.34 0.66
29 29 Blood
culture
9 4 ND 1.73 1.26 0.64 0 0.55 0.69 0.77
30 30 Blood
culture
17 2 0.01 1.18 1.04 1.09 0.98 0.78 2.08 0.75
Table 3 | Characteristics and fluconazole treatment features in six
patients infected with C. glabrata that acquired in vitro resistance
under fluconazole treatment.
Patient
no.
Age
(yr)/sex
Underling
disease
No. of positive
culture
(sampling
times in days)
Fluconazole
treatment dosage
(administration
days)
1 43/M Nephrolithiasis 3 (0, 60, 150) 200mg (60–80)
2 42/F Diabetes 2 (0, 30) 200mg (0–28)
3 53/F Asthma
(corticotherapy)
5 (0, 150, 220,
250, 280)
150mg (120–135),
100mg (150–165),
400mg (225–232),
200mg (250–257)
4 72/F Nephrolithiasis
and diabetes
3 (0, 130, 446) 400mg (130–160)
an increase in gene copy number, respectively. Regarding quan-
titative analysis, fluconazole MIC values were log-transformed,
standardized and centered. The effect on fluconazole MICs due
to the gene copy number and expression levels of each of the
four genes studied was modeled using the Genmod procedure. All
first-level interactions (the product of the two main effect terms)
between each covariate were tested. When an interaction was sta-
tistically significant, each of the two main effects was retained in
the model, regardless of the level of statistical significance. The
most parsimonious best-fitting model was selected using the log-
likelihood ratio test. After selection of the model, the generalized
estimating equation option was used to account for the non-
independence of isolates sampled from a same patient. Statistical
analyses were performed with SAS 9.2 statistical software (Cary,
NC, USA). All statistical tests were two-sided, and p < 0.05 was
considered significant.
RESULTS
The characteristics of the 43 C. glabrata clinical isolates col-
lected during a hospital survey from 30 patients (9 patients
had ≥2 episodes) at the Habib Bourguiba University hospital
in Sfax (Tunisia) are detailed in Table 2. Briefly, most isolates
were grown from urine samples, and 15 isolates were involved
in invasive infections. Fluconazole MICs ranged from 0.016 to
256mg/l; MIC50 and MIC90 were 4mg/l and 256mg/l, respec-
tively. Nine isolates were classified as resistant to fluconazole with
a MIC >256mg/l. Microsatellite analysis displayed 17 distinct
genotypes. Twenty-two isolates were sequentially collected (7–220
days lag in the same patient). In patients 1, 2, 3, and 4 treated
with fluconazole, MICs were significantly increased in sequential
C. glabrata isolates, whereas the microsatellite-based genotypes
remained stable (Tables 3, 4). These patients were exposed to
150, 30, 220, or 120 days of fluconazole therapy with a cumula-
tive dose of 4, 5.6, 8, and 12 g fluconazole, respectively (Table 3).
In patients 6 and 11, the fluconazole MICs were increased in
sequential isolates with a distinct microsatellite genotype, thereby
indicating that they probably acquired resistantC. glabrata strains
upon exposure to fluconazole (Table 2). Finally, both microsatel-
lite genotypes and fluconazole MICs remained stable in the
sequential isolates derived from patients 19, 21, and 26 (Table 2).
CgCDR1, CgPDH1, CgSNQ2, AND CgERG11 EXPRESSION
To investigate the mechanism of fluconazole resistance in
C. glabrata we analyzed the gene expression levels of CgCDR1,
CgPDH1, CgERG11, and CgSNQ2. In the 43 C. glabrata isolates,
the normalized gene expression levels were as follows: CDR1 lev-
els ranged from 0.010 to 92.61, median 0.415 IQR [0.120–1.825];
CDR2 levels ranged from 0.04 to 375.57, median 0.91 IQR [0.46–
3.59]; SNQ2 levels ranged from 0.010 to 73.61, median 0.575 IQR
[0.34–1.72] and ERG11 levels ranged from 0 to 4.34, median 0.54
IQR [0.27–1.00] (Table 2).
When considering the nine fluconazole resistant isolates,
CgCDR1 was overexpressed in five isolates, CgPDH1 was overex-
pressed in six isolates, CgSNQ2was overexpressed in three isolates
and CgERG11 was overexpressed in one isolate (Table 2). Overall,
the expression of the efflux pump genes CgCDR1, CgPDH1,
and CgSNQ2 was increased in two resistant isolates compared
with the susceptible initial isolates. One resistant isolate dis-
played simultaneous overexpression of CgCDR1, CgPDH1 and
CgERG11, while another isolate displayed overexpression of both
CgPDH1 and CgSNQ2. CgCDR1 and CgPDH1 were each overex-
pressed in two resistant isolates. In contrast, at least one gene was
overexpressed in nine fluconazole susceptible isolates. Although
overexpression of CgERG11 was never observed, CgPDH1,
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CgCDR1 and CgSNQ2were overexpressed in seven, three and two
fluconazole-susceptible isolates, respectively (Table 2). In four of
these isolates, CgPDH1 overexpression was observed in parallel
with either CgSNQ2 or CgCDR1 overexpression. When consid-
ering sequential isolates derived from the same patients, the
acquisition of fluconazole resistance was associated with increased
expression of CgCDR1 and CgPDH1 in patient 1 and increased
expression of CgPDH1 in patient 4 (Table 4).
CgCDR1, CgPDH1, CgSNQ2, AND CgERG11 COPY NUMBER
To investigate one possible mechanism of C. glabrata fluconazole
resistance we analyzed gene copy number of CgCDR1, CgPDH1,
CgERG11, and CgSNQ2. The normalized gene copy number val-
ues were as follows: CDR1 copy numbers ranged from 1.02 to
4.70, median 1.71 IQR [1.2–2.18]; CDR2 copy numbers ranged
from 0.00 to 5.70, median 1.43 IQR [1.14–1.98]; SNQ2 copy
numbers ranged from 0.18 to 364.12, median 1.22 IQR [0.77–
1.61] and ERG11 copy numbers ranged from 0.55 to 1549.94,
median 1.51 IQR [1.13–2.20]. In some isolates, either overexpres-
sion or increased gene copy number was observed for CgCDR1
and CgPDH1 (Table 2). Nevertheless, three out of five resistant
isolates that displayed CgCDR1 overexpression also displayed an
increase in CgCDR1 gene copy number (4.7, 4.04 and 3.64 copies
for isolates 1.2, 6.2, and 8, respectively) (Table 2). Three of the
six resistant isolates that displayed CgPDH1 overexpression also
exhibited an increase in CgPDH1 gene copy number (2.71, 4.13,
and 5.7 copies in isolates 7, 1.2, and 6.2, respectively). Similarly,
resistant isolates displaying CgERG11 overexpression also exhib-
ited an increase in CgERG11 gene copy number (12.7 times more
than TU10). For CgSNQ2, gene overexpression did not corre-
late with gene copy number (Table 2). Among the fluconazole
susceptible isolates, the copy number of at least one gene was
increased in seven isolates. More precisely, copy number of the
four genes was increased in isolate 21.2, while only one gene
copy number was increased in the remaining isolates as follows:
CgERG11 copy number was increased in four isolates and the gene
copy number of CgSNQ2 and CgCDR1 was increased, each in
one isolate.
POPULATION-BASED GENE INTERACTION STUDY
Univariate correlation analysis indicated a complex interaction
between gene copy number and expression levels (Table 5). A
correlation between CgPDH1, CgCDR1, and CgSNQ2 gene copy
numbers was observed, while a correlation between the expres-
sion levels of CgPDH1, CgERG11, and CgSNQ2 was also found.
Fluconazole MIC values positively correlated with both CgCDR1
and CgSNQ2 expression levels. A positive correlation between
gene copy number and expression level was observed only for
the CgPDH1 gene. Figure 1 summarizes the significant combined
main effects and first-level interactions between gene copy num-
ber and gene expression levels influencing fluconazole MIC levels
in C. glabrata.
The best-fitting multivariate model of the factors influenc-
ing fluconazole MIC values included (i) the main effects of the
expression levels of CgSNQ2, CgERG11, and CgPDH1 and the
gene copy number of CgPDH1 and (ii) the interaction between
CgSNQ2 and CgERG11 gene expression and the interaction
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Table 5 | Spearman rank correlation coefficients between the fluconazole MICs and the normalized expression level and copy number of CDR1,
PDH1, ERG11, and SNQ2 genes.
Fluconazole Gene expression Gene copy number
MIC CDR1 PDH1 ERG11 SNQ2 CDR1 CDR2 ERG11
GENE EXPRESSION
CDR1 0.50551
PDH1 0.21498 0.38320
ERG11 0.11168 0.04558 0.34565
SNQ2 0.38022 0.41744 0.58012 0.33921
GENE COPY NUMBER
CDR1 0.04854 0.19972 0.18646 −0.04077 −0.00235
PDH1 −0.04227 0.29146 0.36136 0.18184 0.06981 0.62306
ERG11 0.30065 0.18173 −0.05340 −0.00061 0.09112 0.43376 0.32972
SNQ2 0.29037 0.01279 −0.07420 −0.07782 −0.13971 0.17851 0.24155 0.29510
The Spearman rank correlation coefficient values >0.3 (and p < 0.05) are bolded.
FIGURE 1 | Illustration of the effect of the complex interactions
between CgPDH1, CgSNQ2, and CgERG11 drug resistance gene copy
numbers and expression levels on fluconazole resistance in Candida
glabrata clinical isolates. CgPDH1 gene copy number and expression
were correlated, and their interaction led to an increase in fluconazole MIC
levels. In contrast, the main effect of CgPDH1 overexpression
independently led to a decrease in MIC levels. The main effect of CgSNQ2
overexpression independently promoted an increase in fluconazole MIC
levels, while its interaction with CgERG11 expression led to a decrease in
MIC levels.
between CgPDH1 copy number and expression. In this model,
C. glabrata fluconazole MICs were significantly increased due
to both CgSNQ2 overexpression (p < 10−4) and the interaction
between CgPDH1 copy number and expression (p = 0.038). In
contrast, both CgPDH1 overexpression (p = 0.049) and the inter-
action between CgSNQ2 and CgERG11 expression (p = 0.003)
led to a statistically significant decreased in fluconazole MICs.
Neither CgERG11 expression (p = 0.823) nor CgPDH1 gene
copy number (p = 0.985) independently displayed a statistically
significant influence on fluconazole MICs. These multivariate
analysis findings are illustrated in Figure 1.
DISCUSSION
This population-based approach allowed us to confirm the find-
ing that ABC transporter familymembrane gene overexpression is
a pivotal fluconazole resistance mechanism in clinical C. glabrata
isolates, which had been previously evidenced primarily using
laboratory strains. Moreover, this study enabled us to further
elucidate the main effects and complex interactions between
gene expression and copy number associated with in vitro flu-
conazole resistance. The population-based analysis revealed that
CgPDH1 and CgERG11 overexpression indirectly influence flu-
conazole MIC levels by increasing CDR1 and SNQ2 expression
levels. Although CgERG11, CgSNQ2, and CgPDH1 expression
and, to a lesser extent, copy number levels were significantly
associated with fluconazole resistance, our findings highlight the
complex interaction between these genes and suggest the involve-
ment of unmeasured confounding effects. Indeed, mutations in
CgPDR1, CgERG11 or others genes that might impact C. glabrata
fluconazole resistance were not analyzed in this study. Univariate
analysis (Table 5) suggested that CgCDR1 overexpression plays a
major role in the regulation of MIC levels. However, its effect did
not remain significant in the multivariate analysis, which high-
lighted the major independent effect of CgSNQ2 overexpression.
Both univariate and multivariate analyses showed that copy num-
ber and overexpression were markedly correlated for CgPDH1
but not for the other genes. In patient 1, for whom sequential
C. glabrata isolates displayed a stable genotype, switching to flu-
conazole resistance was associated with both overexpression and
increased gene copy number of CgPDH1 (Table 4). A high corre-
lation between the expression levels of all membrane transporter
genes was detected, which is probably because they are controlled
by the same transcription factorCgPDR1 (Ferrari et al., 2009; Paul
et al., 2011). This transcription factor has been associated with
both resistance to azole antifungals via the overexpression of ABC
transporter genes and enhanced virulence in C. glabrata due to
gain-of-function mutations (Ferrari et al., 2009).
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CgCDR1 and CgPDH1 overexpression-driven drug efflux is
the most frequent fluconazole resistance mechanism observed in
C. glabrata (Miyazaki et al., 1998; Sanglard et al., 1999, 2001;
Wada et al., 2002; Coleman and Mylonakis, 2009). Numerous
reports have documented acquired resistance upon exposure to
long-term fluconazole therapy (Coste et al., 2007; Shin et al.,
2007), as observed in the four patients who acquired resistant iso-
lates (Table 3). Although CgCDR1 and CgPDH1 expression could
not be determined in the fluconazole susceptible isolate, overex-
pression of both genes was associated with fluconazole resistance
in the isolate derived from patient 2. Acquisition of both CgPDH1
overexpression and increased gene copy number was observed in
isolates derived from patient 1 (Table 4).
An overproduction of lanosterol-demethylase in C. glabrata
has initially been described by Marichal et al. who found that
duplication of the entire chromosome E (Marichal et al., 1997),
the chromosome on which ERG11 is located, was associated
with a four-fold increase in ERG11 copy number in flucona-
zole resistant compared with susceptible isolates. A recent study
has also shown that lanosterol-demethylase overproduction, for
which the mechanism is unknown, was involved in fluconazole
resistance (Redding et al., 2003). In our study, an increase in
CgERG11 gene copy number was associated with CgERG11 over-
expression in only one isolate. Furthermore, CgCDR1, CgPDH1,
and/or CgERG11 gene copy number was inconsistently associated
with overexpression, thereby suggesting that an increase in gene
copy number might sometime result in gene silencing via either
heterochromatin formation or DNA methylation (Merrick and
Duraisingh, 2006; Mishra et al., 2011).
A strong correlation between CgCDR1, CgPDH1, and
CgERG11 gene copy number was observed (Table 4), although
these genes are located on chromosomes M, F, and E, respectively.
Further genome hybridization experiments may shed light on
the underlying mechanisms and enable the localization of these
amplified genes. Many gene duplication mechanisms have been
described in various regions of the C. glabrata genome. Poláková
et al. have suggested that duplication occurs in chromosomal seg-
ments that encode for some ABC transporter genes (Poláková
et al., 2009). Similarly, Mûller et al. have shown that the mech-
anisms of microevolution of this asexual species include recom-
bination within tandem arrays of repeated genes, which often
encode cell wall proteins, thereby suggesting a possible adaptive
function (Mûller et al., 2009). The fact that some genotypically
identical isolates (genotype 3 and 7, Table 2) displayed different
fluconazole resistance mechanisms support the hypothesis that
fluconazole resistance is chiefly associated with the overexpression
of normally present genes within the C. glabrata genome rather
than gene mutation.
In conclusion, this population-based approach provides fur-
ther evidence that overexpression of membrane transporter genes
is a pivotal fluconazole resistance mechanism in C. glabrata clin-
ical isolates. A high correlation between the expressions of these
genes, which are controlled by the same transcription factor, was
observed. However, the multivariate analysis revealed, for the
first time, that CgSNQ2 exerts a major independent effect on
fluconazole resistance. Regarding the other genes assessed, inter-
actions played a greater role than the main effects in fluconazole
resistance. Notably, CgPDH1 overexpression was significantly
associated with increased gene copy number, which was not
observed with the other genes analyzed. Furthermore, a correla-
tion between gene copy number and fluconazole resistance was
only observed for CgERG11, thereby suggesting that an increase
in copy number ofC. glabratamembrane transporter genes might
result in gene silencing. This study provides only partial insight
intoC. glabrata fluconazole resistancemechanisms, asmany other
mechanisms have not been analyzed, including those targeting
other membrane components. Nevertheless, our findings high-
light the important role that complex gene copy number and
overexpression interactions play in fluconazole resistance, which
should been taken into account in further studies.
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